突变阳性-话题@MedSci - 梅斯（MedSci）

#突变阳性#

46篇内容 | 1582人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1803574, encodeId=53ee18035e4aa, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, objectType=article, longId=729047, objectId=d22fe2904783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22fe2904783, replyNumber=0, likeNumber=93, createdTime=2023-03-08, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22fe2904783, moduleTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d22fe2904783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803573, encodeId=ed7c18035e365, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=105, createdTime=2022-11-23, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803572, encodeId=266d18035e2fe, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=127, createdTime=2022-12-04, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803569, encodeId=ed7518035691d, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=76, createdTime=2022-08-07, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803565, encodeId=9f60180356579, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=77, createdTime=2022-02-18, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803564, encodeId=5cb41803564f5, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, objectType=article, longId=213493, objectId=fdd621349391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd621349391, replyNumber=0, likeNumber=87, createdTime=2021-07-27, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd621349391, moduleTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fdd621349391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803568, encodeId=2aec180356890, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, objectType=article, longId=220696, objectId=2d11220696ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d11220696ee, replyNumber=0, likeNumber=87, createdTime=2022-01-12, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d11220696ee, moduleTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2d11220696ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803566, encodeId=a3441803566c4, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), objectType=article, longId=218470, objectId=7b082184e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b082184e0a7, replyNumber=0, likeNumber=89, createdTime=2021-12-04, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b082184e0a7, moduleTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7b082184e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803570, encodeId=5d5418035e015, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=220889, objectId=d4ae2208892d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ae2208892d, replyNumber=0, likeNumber=104, createdTime=2022-06-24, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ae2208892d, moduleTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d4ae2208892d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803567, encodeId=e962180356e07, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, objectType=article, longId=220083, objectId=ae6a2200837d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6a2200837d, replyNumber=0, likeNumber=98, createdTime=2022-02-01, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6a2200837d, moduleTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ae6a2200837d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803571, encodeId=a56118035e116, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Lancet Oncol：达拉菲尼联合曲美替尼在BRAFV600E突变阳性胶质瘤中的疗效, objectType=article, longId=221246, objectId=2b0d221246c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0d221246c4, replyNumber=0, likeNumber=86, createdTime=2022-10-14, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0d221246c4, moduleTitle=Lancet Oncol：达拉菲尼联合曲美替尼在BRAFV600E突变阳性胶质瘤中的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2b0d221246c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803562, encodeId=816f1803562ba, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, objectType=article, longId=213145, objectId=141f2131458b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141f2131458b, replyNumber=0, likeNumber=101, createdTime=2021-07-21, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141f2131458b, moduleTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=141f2131458b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803563, encodeId=3cc818035637e, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=67, createdTime=2022-06-08, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803559, encodeId=ffa418035597c, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, objectType=article, longId=195816, objectId=65141958168d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65141958168d, replyNumber=0, likeNumber=118, createdTime=2021-03-31, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65141958168d, moduleTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=65141958168d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803561, encodeId=c1251803561be, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, objectType=article, longId=200981, objectId=96e62009817d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e62009817d, replyNumber=0, likeNumber=87, createdTime=2021-04-22, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e62009817d, moduleTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=96e62009817d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803560, encodeId=9a021803560bf, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=CALR基因突变阳性的红细胞增多症1例, objectType=article, longId=197562, objectId=4bb519e56222, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bb519e56222, replyNumber=0, likeNumber=108, createdTime=2020-08-04, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bb519e56222, moduleTitle=CALR基因突变阳性的红细胞增多症1例, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4bb519e56222)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803556, encodeId=f67a180355626, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择, objectType=article, longId=191175, objectId=f0141911e5a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0141911e5a2, replyNumber=0, likeNumber=89, createdTime=2020-10-25, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0141911e5a2, moduleTitle=褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f0141911e5a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803555, encodeId=bfc31803555a8, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, objectType=article, longId=190904, objectId=3990190904f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3990190904f4, replyNumber=0, likeNumber=80, createdTime=2020-07-16, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3990190904f4, moduleTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3990190904f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803553, encodeId=7f5118035536a, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183976, objectId=367f1839e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367f1839e6b1, replyNumber=0, likeNumber=74, createdTime=2020-04-30, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367f1839e6b1, moduleTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=367f1839e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, objectTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, objectType=article, longId=192270, objectId=8c6d1922e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6d1922e0a7, replyNumber=0, likeNumber=75, createdTime=2020-08-25, rootId=0, userName=ms7474195563676018, userId=ee262500130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6d1922e0a7, moduleTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8c6d1922e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突变阳性

2020-05-29

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！

2023-03-08

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-11-23

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-12-04

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2022-08-07

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2022-02-18

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益

2021-07-27

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

A+T在EGFR突变阳性NSCLC的治疗新格局

2022-01-12

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG)

2021-12-04

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效

2022-06-24

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗

2022-02-01

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Lancet Oncol：达拉菲尼联合曲美替尼在BRAFV600E突变阳性胶质瘤中的疗效

2022-10-14

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L

2021-07-21

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2022-06-08

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤

2021-03-31

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益

2021-04-22

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

CALR基因突变阳性的红细胞增多症1例

2020-08-04

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择

2020-10-25

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局

2020-07-16

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**

2020-04-30

ms7474195563676018 (审核中...)

前往app查看评论内容

#突变阳性#

王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理

2020-08-25

科室
- - 订阅+
  - 更多科室
工具
服务